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Influenza vaccination is recommended for people with chronic bronchitis (CB) because they
have a higher risk of influenza-related complications, hospitalizations, and death during
seasonal influenza epidemics.
This study sought to evaluate influenza vaccination coverage among adults with CB and
analyze the factors (predictors) linked to compliance with vaccination recommendations.
Individual data from adults aged 40 years included in the Spanish Health Survey conducted
in 2006 were used. Subjects were classified as chronic bronchitis sufferers if they answered
affirmatively to the question: ‘‘has your doctor told you that you are currently suffering from
chronic bronchitis?’’. To assess influenza vaccination status we used the question, ‘‘did you
have a flu shot in the latest campaign?’’. Independent variables analyzed included sociodemo-
graphic, health-related variables, self-reported presence of other concomitant chronic
diseases, and use of health-care services.
The percentage of subjects who were reported to be suffering from CB was 6.6% (NZ 1320,
95% CI 6.2e6.9%). The influenza vaccination coverage among CB sufferers was 63.6% compared
with 48.6% for nonsufferers (p < 0.05). The predictors significantly associated with a higher
likelihood of receiving the vaccine among adult CB sufferers were: higher age; male gender;
nonsmoker or ex-smoker status; doing physical exercise; and suffering from concomitant
asthma or diabetes.
We conclude that influenza vaccination coverages among Spanish adults suffering from CB
are below desirable levels; thereby making it necessary for strategies to be implemented
aimed at improving the use of influenza vaccine among such patients.
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Influenza vaccination in adults with chronic bronchitis 1519Introduction
Subjects suffering from chronic lung diseases, including
chronic bronchitis (CB), have a higher risk of influenza-
related complications, hospitalizations, and death during
seasonal influenza epidemics.1e6
In Spain, a study conducted to estimate excess hospital
admissions of influenza-related diseases during four
epidemic influenza periods observed that chronic bronchitis
was the second leading influenza-related disease after
pneumonia.4
Schanzer et al estimated age-specific influenza-attrib-
utable mortality rates in Canada, stratified by the presence
of chronic conditions, from 1994 to 2000, and reported that
there were approximately 4000 influenza-attributable
deaths per year (equivalent to a rate of 14 per 100,000
population), with chronic lung disease being present in over
50% of all patients whose death was attributed to
influenza.5
The effectiveness of influenza vaccination among
patients with chronic respiratory diseases has been shown
in both clinical trials and observational studies.6e8
In a systematic review of the Cochrane database, in
which six randomized clinical trials with influenza vaccines
in chronic obstructive pulmonary disease (COPD) sufferers
were assessed, a significant decrease in the total number of
exacerbations was observed among vaccinated subjects
versus those who received placebo.6 In these trials, influ-
enza vaccination also reduced the development of severe
respiratory complications and hospitalization by 50e80%,
and death from both respiratory disease and all causes by
40e55%.6
Seasonal influenza vaccine for patients with chronic
pulmonary diseases is recommended by the public health
authorities in USA and all European countries.9,10
Since 1992, the Spanish Ministry for Health and
Consumer Affairs has included all subjects who suffer from
chronic lung diseases in its annual influenza vaccine
recommendations, with vaccination being administered
free of charge in all such cases.11
Developing and implementing methods for the
measurement of and feedback about the progress of
national and local influenza control programs, including
vaccine coverage, form part of the priority goals set by the
World Health Organization and European Union Public
Health Program.9,12,13 Coverage studies enable compliance
with prevailing guidelines to be ascertained, associated
factors to be studied, and non-complying subjects to be
characterized and identified.9,12e16 Furthermore, these
studies are of help for the purposes of drawing up appro-
priate strategies to improve goals, providing data in support
of decision-making, and managing vaccination pro-
grams.9,12e16
To our knowledge, no specific studies on influenza
vaccination coverage and factors associated with vaccine
uptake, using a representative sample of adults suffering
from chronic bronchitis, have been conducted in Spain.
Previous studies that included subjects suffering from
‘‘chronic lung diseases’’ have been published, and report
vaccination coverages ranging from 41% to figures in excess
of 87%.17e19Based on data drawn from the 2006 National Health
Survey, this study aimed at:
1. ascertaining influenza vaccination coverages among
Spanish adults suffering from chronic bronchitis;
2. analyzing which sociodemographic, health-related
variables, and use of health-care services variables
were associated with the likelihood of Spanish chronic
bronchitis sufferers being vaccinated.Patients and methods
A descriptive cross-sectional study was conducted on
influenza vaccination coverage nationwide, using data
drawn from the 2006 Spanish National Health Survey (NHS).
The 2006 NHS was conducted by the National Statistics
Institute (Instituto Nacional de Estadı´stica e INE ) under
the aegis of the Spanish Ministry of Health and Consumer
Affairs.20,21
The survey covered a nationwide, representative sample
of Spain’s non-institutionalized population residing in main
family dwellings. Study subjects were selected by means of
probabilistic multistage sampling, with the first-stage units
being census sections, and the second-stage units, main
family dwellings. Information was collected by home-based
personal interview. The data-collection period started in
June 2006 and ended in June 2007. Details of the NHS
methodology are described elsewhere.20,21
For study purposes, subjects aged 40 years and over
were selected. We identified individuals suffering from
chronic bronchitis as those that answered ‘‘yes’’ to the
question, ‘‘has your doctor told you that you are currently
suffering from chronic bronchitis?’’.
To assess influenza vaccination status we considered the
response (yes or no) to the question, ‘‘did you have a flu
shot in the latest campaign?’’. The following were analyzed
as independent variables: (a) sociodemographic charac-
teristics, such as age, sex, educational level (age of
conclusion of formal education), and monetary income; (b)
health-related variables, namely, (1) self-rated health
status, (2) smoking habit (nonsmokers, ex-smokers, and
current smokers), (3) obesity (body mass index 30, BMI
was calculated from self-declared weight and height), (4)
alcohol consumption, (5) physical exercise, and (6) self-
reported presence of other concomitant chronic diseases
(asthma, chronic heart disease, diabetes and depression);
and (c) use of health-care services, i.e., (1) physician visits
in the preceding four weeks, (2) hospitalizations in the
preceding 12 months, and (3) emergency room attendance
in the preceding 12 months.
Among vaccinated subjects, we then analyzed the reasons
for which vaccine had been received. These included three
possible categories, namely, ‘‘on doctor’s orders’’, ‘‘on
request’’, and ‘‘vaccination in the workplace’’.
Statistical analysis
We first estimated the prevalence of Spanish adults who
suffered from chronic bronchitis (CB), described their
distribution according to the study variables, and compared
1520 R. Jime´nez-Garcı´a et al.these figures against those for the non-CB population.
Second, we estimated and compared age- and sex-adjusted
vaccination coverages, among those with and without CB,
according to the study variables.
In addition, we also described the reasons given by CB
sufferers for having been vaccinated.
The c2 statistical method was used for bivariate
comparison of proportions, and statistical significance was
set at two-tailed a < 0.05.
Third, multivariate logistic regression models were
generated so that, by using influenza vaccination as the
dependent variable, we could then determine which of the
variables covered was independently associated with
influenza vaccination (predictors) among CB sufferers.
The logistic regression multivariate model was built using
the ‘‘enter modelling’’ method. The process included four
steps: first, bivariate analysis of each variable; second,
selection of variables for the multivariate analysis. We
included all the variables whose bivariate tests were signif-
icant and those we considered scientifically relevant
according to the references reviewed. Third, in order to fit
the multivariate model the importance of each variable
included in the model was verified. To do this we examined
the Wald statistic for each variable and compared each
estimated coefficient with the coefficient from the bivariate
model containing only that variable. Variables that did not
contribute to the model based on this criterion were elimi-
nated and a new model was fitted. The new model was
compared to the old model using the LR test. This process of
deleting, refitting and verifying continues until all the
important variables were included in the model. Fourth,
once the model was obtained, we looked more closely at the
variables included (linearity) and checked for possible
interactions.
Estimates weremade using the ‘‘svy’’ (survey commands)
functions of the STATA program, which enabled us to
incorporate the sampling design and weights into all our
statistical calculations (descriptive, Chi-squared, logistic
regression).Table 1 Distribution by sociodemographic variables, self-rated h
and without chronic bronchitis, according to the 2006 National H
Variable Categories Chronic
Yes [NZ
(95% CI)
Age (mean 95% CI)a Years 67.9 (67
Sexa Female 54.4 (51
Male 45.6 (42
Educational levela 16 years 83.0 (81
>16 years 17.0 (14
Monthly incomea V1200 64.7 (62
>V1200 35.3 (32
Self-rated healtha Excellent/good 21.1 (18
Fair/poor/very poor 78.9 (76
Smoking habita Smoker 19.6 (17
Ex-smoker 32.2 (29
Nonsmoker 48.2 (45
Total 6.6 (6.2
a Statistically significant association on comparing the distribution oResults
We analyzed a total of 20,060 records pertaining to indi-
vidual adult (40 years) participants in the 2006 NHS. The
percentage of subjects that reported that their doctor had
told them they were suffering from CB was 6.6 (NZ 1320,
95% CI 6.2e6.9).
Tables 1 and 2 show the distribution according to the
study variables among CB sufferers and nonsufferers.
Spanish adults who suffered from CB were significantly
older, more male predominant, and had a lower educa-
tional level and income than nonsufferers. Only 21.1% of
CB sufferers regarded their health as having been good or
excellent in the preceding year compared with 55.5%
of nonsufferers. The prevalence of ex-smokers and obesity
was significantly higher among adults with CB, while the
prevalence of alcohol consumption and physical exercise
was lower. All the chronic diseases analyzed and all the
variables related with the use of health-care services
showed significantly higher proportions among CB
sufferers.
Tables 3 and 4 show age- and sex-adjusted influenza
vaccination coverages, broken down by the different vari-
ables analyzed.
The proportion of CB sufferers that reported having been
vaccinated in the most recent campaign (coverage) was
63.6% compared with 48.6% for nonsufferers (p < 0.05).
Bivariate analysis of coverages among CB sufferers
showed that the percentage of vaccinated subjects rose
significantly with age, with the highest coverages being
attained in subjects aged 75 years and over (79.8%). In
contrast, vaccination uptake was significantly lower among
females and among subjects with higher educational level
or monthly income.
There was a significantly higher percentage of vaccina-
tion among adults with CB who were nonsmokers or ex-
smokers than among those who were smokers at the date of
study.ealth, and smoking habit among adults (aged 40 years) with
ealth Survey (NHS).
bronchitis Total
1320] % No [NZ 18,740] %
(95% CI)
[NZ 20,060] %
(95% CI)
.2e68.6) 59.8 (59.6e60.0) 60.4 (60.2e60.6)
.7e57.1) 62.5 (61.8e63.2) 61.9 (61.3e62.6)
.9e48.3) 37.5 (36.8e38.2) 38.1 (37.4e38.7)
.0e85.0) 69.2 (68.5e69.9) 70.1 (64.5e70.7)
.9e19.0) 30.8 (30.1e31.4) 29.9 (29.2e30.5)
.1e67.3) 49.2 (48.4e49.9) 50.2 (49.5e50.9)
.7e37.9) 50.8 (50.1e51.5) 49.8 (49.1e50.5)
.9e23.3) 55.5 (54.8e56.2) 53.3 (52.6e54.0)
.6e81.1) 44.5 (43.7e45.2) 46.7 (46.0e47.4)
.5e21.8) 21.8 (21.2e22.4) 21.7 (21.1e22.2)
.7e34.7) 22.5 (21.9e23.1) 23.2 (22.6e23.7)
.5e50.9) 55.6 (54.9e56.3) 55.1 (54.5e55.8)
e6.9) 93.4 (93.1e93.8) 100
f variables between adults with and without chronic bronchitis.
Table 2 Distribution by lifestyle variables, concomitant chronic diseases, and use of health-care services among adults (aged
40 years) with and without chronic bronchitis, according to the 2006 National Health Survey (NHS).
Chronic bronchitis Total
Yes [NZ 1320] %
(95% CI)
No [NZ 18,740] %
(95% CI)
[NZ 20,060] %
(95% CI)
Obesity (BMI)a 41.5 (38.9e44.2) 30.3 (29.7e31.0) 31.1 (30.4e31.7)
Alcohol consumptiona 45.5 (42.8e48.1) 51.2 (50.5e51.9) 50.8 (50.2e51.5)
Physical exercisea 55.1 (52.5e57.8) 60.7 (60.0e61.4) 60.3 (59.6e70.0)
Asthmaa 34.1 (31.5e36.6) 3.5 (3.3e3.8) 5.5 (5.2e5.8)
Chronic heart diseasea 28.7 (26.3e31.1) 11.2 (10.7e11.6) 12.3 (11.9e12.8)
Diabetesa 16.2 (14.2e18.2) 9.9 (9.4e10.3) 10.3 (9.9e10.7)
Depressiona 34.4 (31.8e36.9) 19.7 (19.1e20.2) 20.6 (20.1e21.2)
Physician visits in the preceding 4 weeksa 66.2 (63.6e68.8) 46.4 (45.7e47.1) 47.7 (47.0e48.4)
Hospitalizations in the preceding 12 monthsa 23.4 (21.1e25.7) 9.8 (9.4e10.2) 10.7 (10.2e11.1)
ER attendance in the preceding 12 monthsa 44.5 (41.9e47.2) 25.3 (24.7e26.0) 26.6 (26.0e27.2)
ER: emergency room.
a Statistically significant association on comparing the distribution of variables between adults with and without chronic bronchitis.
Influenza vaccination in adults with chronic bronchitis 1521Vaccination coverage was also higher among individuals
who perceived their healthmore negatively and among those
who reported doing physical exercise. A higher proportion of
adults with CB who suffered from a concomitant chronic
condition, such as asthma or diabetes, was vaccinated than
were those without these concomitant diseases.
Lastly, adults with CB who had visited their physician in
the preceding four weeks also showed higher coverages.
On being questioned as to their reason for having influ-
enza vaccination, most vaccinated CB sufferers (86.9%)
cited ‘‘on doctor’s orders’’, while 9% checked the ‘‘on
request’’ option. Among those without CB, these percent-
ages were 76.8% and 17.1%, respectively (p < 0.05).
The results of the multivariate analysis are shown in
Table 5. The factors that were independently and signifi-
cantly associated with a higher likelihood of receiving theTable 3 Influenza vaccination coverage by sociodemographic v
(aged 40 years) with and without chronic bronchitis (CB), accor
Variable Category Influ
Adu
Ageb,c 40e64 years 40.7
65e74 years 73.6
75 years 79.8
Sexb,c Female 59.9
Male 68.1
Educational levelb,c 16 years 68.2
>16 years 41.1
Monthly incomeb,c V1200 67.5
>V1200 57.0
Self-rated healthb,c Excellent/good 51.2
Fair/poor/very poor 66.9
Smoking habitb,c Smoker 40.5
Ex-smoker 69.9
Nonsmoker 68.9
Total 63.6
a Age- and sex-adjusted vaccination coverages.
b Statistically significant association on analyzing vaccine coverages
c Statistically significant association on analyzing vaccine coveragesvaccine (predictors) among adult CB sufferers were as
follows: higher age; male gender; nonsmoker or ex-smoker
status; doing physical exercise; and suffering from
concomitant asthma or diabetes.
Discussion
The results of this study show that influenza vaccination
coverage among Spanish adults suffering from chronic
bronchitis is below desirable levels; and that 37.4% of them
were not vaccinated in the last campaign and are thus
possibly unprotected against influenza.
Using different methodologies, a number of authors
have examined the prevalence and predictors of influ-
enza vaccination among patients with chronic lung dis-
eases.17e19,22e30ariables, self-rated health, and smoking habit among adults
ding to the 2006 National Health Survey (NHS).
enza vaccination coveragea
lts with CB % (95% CI) Adults without CB % (95% CI)
(36.4e45.1) 16.1 (15.5e16.8)
(69.1e78.2) 57.4 (55.8e59.1)
(76.2e83.4) 73.1 (71.6e74.7)
(56.6e63.2) 45.7 (44.8e46.6)
(64.7e71.5) 52.2 (50.9e53.5)
(65.7e70.8) 52.0 (51.2e52.9)
(35.4e46.8) 30.8 (29.4e32.2)
(64.5e70.4) 53.4 (52.3e54.4)
(53.1e60.9) 40.8 (39.7e41.9)
(46.0e56.5) 36.2 (35.3e37.1)
(64.3e69.6) 54.5 (53.3e55.6)
(35.0e46.1) 24.0 (22.5e25.6)
(66.0e73.7) 54.7 (53.0e56.5)
(65.4e72.3) 53.7 (52.8e54.7)
(61.3e66.0) 48.6 (47.9e49.4)
among adults with chronic bronchitis.
among adults without chronic bronchitis.
Table 4 Influenza vaccination coverage by lifestyle variables, concomitant chronic diseases, and use of health-care services
among adults (aged 40 years) with and without chronic bronchitis (CB), according to the 2006 National Health Survey (NHS).
Variable Influenza vaccination coveragea
Adults with CB % (95% CI) Adults without CB % (95% CI)
Obesityc No 60.2 (57.0e63.3) 45.8 (44.8e46.7)
Yes 68.5 (64.9e72.0) 53.2 (51.9e54.5)
Alcohol consumptionc No 66.5 (63.3e69.7) 52.7 (51.6e53.8)
Yes 60.0 (56.7e63.6) 44.0 (42.9e45.1)
Physical exerciseb,c No 60.0 (56.4e63.5) 46.8 (45.5e48.0)
Yes 66.6 (63.5e69.7) 49.7 (48.7e50.6)
Asthmab,c No 60.6 (57.7e63.5) 47.8 (47.0e48.6)
Yes 69.5 (65.5e73.6) 61.4 (57.6e65.3)
Chronic heart diseasec No 60.0 (56.2e61.8) 43.1 (42.3e43.9)
Yes 75.2 (70.9e79.5) 66.4 (64.4e68.4)
Diabetesb,c No 61.7 (59.1e64.2) 46.5 (45.7e47.4)
Yes 73.8 (68.2e79.4) 62.6 (60.4e64.8)
Depressionc No 64.0 (61.1e66.8) 49.0 (48.1e49.9)
Yes 63.0 (58.9e67.0) 49.7 (48.1e51.3)
Physician visits in the preceding 4 weeksb,c No 57.8 (53.7e62.0) 41.3 (40.2e42.5)
Yes 66.6 (63.7e69.4) 54.3 (53.3e55.4)
Hospitalizations in the preceding 12 monthsc No 61.6 (58.9e64.3) 45.9 (45.1e46.7)
Yes 70.2 (65.5e74.9) 58.6 (56.1e61.0)
ER attendance in the preceding 12 monthsc No 61.1 (57.9e64.2) 46.1 (45.2e47.0)
Yes 66.8 (63.3e70.3) 53.2 (51.7e54.7)
ER: emergency room.
a Age- and sex-adjusted vaccination coverages.
b Statistically significant association on analyzing vaccine coverages among adults with chronic bronchitis.
c Statistically significant association on analyzing vaccine coverages among adults without chronic bronchitis.
1522 R. Jime´nez-Garcı´a et al.A study based on the 2005 Canadian Community Health
Survey showed that coverage for subjects aged 12 or over
suffering from ‘‘emphysema or chronic bronchitis’’ was
57%.22 Studies using primary care databases and conducted
in the United Kingdom for the period 2004/2005 obtained
coverages of 36.1% and 23.8% for respiratory-diseaseTable 5 Predictors of influenza vaccination among
Spanish adults (aged 40 years) suffering from chronic
bronchitis, according to the 2006 National Health Survey
(NHS).
Adjusted
OR
95% Confidence
interval
Age 40e64 years 1 e
65e74 years 3.13 (2.28e4.30)
75 years 4.34 (3.15e5.97)
Sex Female 1 e
Male 1.41 (1.03e1.93)
Smoking
habit
Smoker 1
Ex-smoker 1.73 (1.20e2.50)
Nonsmoker 1.80 (1.23e2.62)
Physical
exercise
No 1 e
Yes 1.46 (1.13e1.88)
Asthma No 1 e
Yes 1.45 (1.11e1.90)
Diabetes No 1 e
Yes 1.54 (1.08e2.19)sufferers aged 65 and <65 years, respectively.23,24 In
2004, Kroneman et al used telephone surveys to undertake
a study in four European countries and reported that
coverages among individuals aged 15 years with ‘‘lung
disease’’ were 8% in Poland, 11% in Sweden, 20% in
Germany, and 30% in Spain.25
A study that targeted COPD sufferers over the age of 40
years attended to at Spanish health centers, observed
a coverage of 87%.17 Another study, which also used primary
care computer databases, reported a coverage of 64.4%
among elderly Spanish with chronic lung disease.26
Until 2006, Spanish National Health Surveys (NHS)
collected information on the presence of ‘‘asthma and/or
chronic bronchitis and/or emphysema’’ in a single question,
and consequently disease-specific coverage could not be
estimated.18,19 Influenza vaccination coverages in the 1993,
1995e1997, 2001 and 2003 Spanish National Health Surveys
among subjects aged 16 years or over suffering from any of
these respiratory diseases were 44.7%, 45.6%, 44.4% and
54.7%, respectively.18,19
Coverages in 2006 appear to have remained stable vis-a`-
vis the results obtained three years previously, in that,
according to the 2003 NHS, elderly subjects (aged 65 years
and over) registered a coverage of 77.8%, a proportion
almost identical to the value obtained in 2006 (77.4%).19
The results yielded by our study and a comparison with
other countries suggest that, as is the case with influenza
vaccination coverage in subjects aged 65 and over, Spain
possibly ranks among the developed countries having the
highest coverages for this high risk group.9,17e19,22e27
Influenza vaccination in adults with chronic bronchitis 1523Few published studies have specifically analyzed the
factors associated with a higher likelihood of influenza vacci-
nation among subjects with chronic lung disease.17e19,27e30
The progressive increase in influenza coverage with age
observed in our population has been reported in patients
with chronic lung diseases or other high risk conditions by
other studies conducted in Spain and elsewhere.15,17e19,27e31
In Canada among the subjects suffering from COPD those
aged >70 had 2.4 times more probability of being vacci-
nated than those aged >40.30
In Germany, Schoefer et al analyzed the vaccination
status and its determinants in 2131 patients with asthma
and/or COPD attended to at a specialized respiratory-
medicine center, and found that vaccination rates dis-
played a significant upward trend with age (adjusted OR for
age group with nine categories, 1.68; 95% CI 1.54e1.84).27
In our population, as in that of other studies, 65 years
marks the age from which a significantly higher proportion
of subjects receive the influenza vaccine. Rather than
being due to patient status, disease severity or the pres-
ence of concomitant chronic conditions, we feel that this is
chiefly due to entry into the age group for which vaccina-
tion is universally indicated.17e19,22e25,27,30,31 This conclu-
sion is coherent with the evidence that age-based
strategies are more successful in increasing vaccine
coverage than patient-selection strategies based on
medical conditions.32
When vaccination-related factors were analyzed, both
the crude and adjusted results of our study were found to
indicate a greater use of vaccines among men than among
women. While most studies previously conducted in Spain on
influenza complications (respiratory or cardiovascular disease
or diabetes) among high risk groups, report this relationship
between gender and influenza vaccination,17e19,32,34 other
studies which have been undertaken elsewhere specifically
targeting subjects with chronic respiratory diseases have
failed to observe this relationship or even found higher
coverages among females.27e30 Further studies in Spain are
thus necessary to explain this association.
Our results also reflect that patients with healthier
lifestyles, ex-smokers or nonsmokers, and those who do
physical exercise are vaccinated to a greater extent than
their less healthy counterparts. Previous studies conducted
among persons suffering from lung conditions have identi-
fied several unhealthy lifestyles, including tobacco use,
alcohol consumption, doing no physical exercise, or having
a body mass index of over 30, as negative predictors for
influenza vaccination.17e19,27,30
In the multivariate analysis, the influence exerted by the
presence of associated asthma and diabetes on influenza
coverage was observed. It is only logical to surmise that
suffering from a concomitant chronic condition would
influence the likelihood of being vaccinated, for at least
two reasons: first, suffering from asthma and diabetes
constitutes an indication for vaccination per se in Spain,11
and suffering from another chronic condition has been
described by other authors as a positive predictor for the
influenza vaccine among chronic lung disease sufferers18;
second, suffering from more than one chronic condition
would probably result in more frequent use of health-care
services, and such subjects are therefore more likely to
receive recommendations to be vaccinated from theirmedical practitioners. Other published studies have like-
wise observed that patients who make the greatest number
of visits to their general practitioner, especially if it is
always the same practitioner, have a higher possibility of
being vaccinated.14,15,17,19,22,33 This is also coherent with
our results, as the reason most cited by patients for being
vaccinated was medical indication.
A recent study conducted in five European countries
identified a number of key factors that would motivate at-
risk populations to seek influenza vaccination, and found
that the most important factor was proactive recommen-
dation by a health professional.31
The vaccination rates for adults (aged 40 years)
included in our study and suffering from other chronic
conditions for which influenza vaccination is also recom-
mended, such as chronic heart diseases and diabetes, were
64.5% and 62.2% respectively. After adjusting by potential
confounders (age and gender) these coverages did not
differ significantly for those described among CB sufferers.
Some organizational strategies that have demonstrated
their effectiveness for the purpose of enhancing vaccina-
tion coverages in target groups and should therefore be
recommended include: telephoning or mailing personal
reminders; compliance monitoring; using computerized
systems to identify high risk patients; improving medical
records; drawing up purpose-made influenza vaccination
timetables; providing education and giving financial incen-
tives to physicians.16,32,35e39
The point should also be made that, in Spain, the general
practitioner (GP) is the main route for administering influ-
enza vaccination, and that patients are normally vacci-
nated in primary care health centers.7,11,26 To our
knowledge, vaccination recommendation rates in respira-
tory specialist settings have not been assessed in Spain and
should be investigated in the future.
Apart from strategies to improve the implementation of
vaccination by providers (general practices and specialists),
available and effective interventions, using public
communications and educational campaigns, must be used
to increase the awareness of and demand for vaccination by
persons with chronic lung disease.16,31,32,35 Educational
campaigns must be targeted at patients with the aim of
enhancing their knowledge regarding the safety, efficacy
and benefits of vaccination.31,32,35e37 Encouraging vacci-
nation should emphasize the need for such preventive care,
regardless of general health status and disease severity,
thereby countering possible perceptions that only seriously
ill individuals need vaccination.35e37 Finally, and as
mentioned above, lowering the age at which the influenza
vaccine recommendation becomes universal is a public
health strategy that must be considered.32
There are a number of possible study limitations. First,
the validity of the questions used by the NHS to classify
subjects as chronic bronchitis sufferers has not been
evaluated. The results of a telephone survey using
a specific questionnaire that addressed the frequency of
respiratory symptoms and knowledge of COPD among 6758
Spanish subjects aged over 40 years, reported that, among
self-reported diagnoses, prevalence of chronic bronchitis
or emphysema was 5.8%. This is a figure similar to ours
and argues in favor of our sample’s representativeness.40
Nevertheless, both this survey and other authors make the
1524 R. Jime´nez-Garcı´a et al.point that underdiagnosis of chronic bronchial diseases is
well recognized in epidemiological studies.40e43
Second, another possible limitation of health surveys is
that the use of unvalidated self-report data on vaccination
could entail possible bias. In this respect, however, several
studies which have compared the results of self-response
against medical records observe that self-response on
influenza vaccination is highly sensitive and evinces a high
degree of agreement.44,45
Third, all information obtained within an interview
context may be subject to recall errors or to the tendency
of individuals to give socially desirable responses. Fourth,
information on relevant variables, such as pharmacological
treatment, use of other recommended vaccines (pneumo-
coccal vaccine) or duration and severity of chronic bron-
chitis, is not collected by Spanish National Health Surveys,
and may act as a confounding factor in certain associations.
Lastly, the initial NHS response rate was 65%, so the
existence of a possible non-response bias should therefore
be considered.21
In conclusion, influenza vaccination coverages among
Spanish adults suffering from chronic bronchitis are below
desirable levels, thereby making it necessary for strategies
to be implemented aimed at improving the use of influenza
vaccine among such patients, and particularly among those
aged under 65 years, females, subjects with unhealthy
lifestyles, and those without other chronic conditions.
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